Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...

The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...

CNW/ - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced that its affiliate Nuvo Pharmaceuticals (Ireland) DAC has acquired the United States rights to ...

The Board of Directors (the Board) has nominated Laura Stoltenberg for election as a new member at the upcoming Annual General Meeting (AGM) in June 2025. She succeeds Stacy Enxing Seng, who, after a ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

Apple this month received approval to launch the Apple Watch's sleep apnea notifications feature in Malaysia, as noted by ...